Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0VGI stock hub

LON/0VGI has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0VGIis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

4.5B

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0VGI

In the news

Latest news · LON/0VGI

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E20

P25 12.9P50 16.9P75 23.5

Trailing P/E12.7

P25 15.9P50 22.9P75 35.8

ROE112.6

P25 -54.2P50 2.1P75 13.7

ROIC18.9

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0VGI market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

190

Groups with data

Currency

USD

Showing 190 of 190 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	United States
Country code	UK
Employees	399
Employees Change	55%
Employees Change Percent	17.24
Enterprise value	$4.6B
Exchange	London Stock Exchange
Financial currency	USD
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	US88322Q1085
Last refreshed	2026-05-10
Market cap	$4.5B
Price	$36.65
Price currency	USD
Rev Per Employee	1,329,267.67x
Sector	Healthcare
Sic	2834
Symbol	lon/0VGI
Website	https://www.tgtherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	7.85%
EV Earnings	13.25x
EV/EBIT	42.23x
EV/EBITDA	41.67x
EV/FCF	-431.12x
EV/Sales	9.01x
FCF yield	-0.24%
Forward P/E	20.02x
P/B ratio	10.09x
P/E ratio	12.74x
P/S ratio	8.4x
PE Ratio3 Y	80.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	21.35%
EBITDA Margin	21.36%
Gross margin	83.05%
Gross Profit	$440.5M
Gross Profit Growth	72.19%
Gross Profit Growth Q	62.76%
Gross Profit Growth3 Y	322.97%
Gross Profit Growth5 Y	276.58%
Net Income	$349.8M
Net Income Growth	1,079.81%
Net Income Growth Q	290.85%
Net Income Growth Quarters	1%
Net Income Growth Years	4%
Pretax Margin	17.46%
Profit Margin	65.95%
Profit Per Employee	$876,682
Profitable Years	3
ROA	8.55
Roa5y	-14.08
ROCE	11.14
ROE	112.6
Roe5y	-23.37
ROIC	18.89

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	-2.27%
Cagr3y	19.67%
Cagr5y	-2.74%
EPS Growth	1,105.5
EPS Growth Q	300
EPS Growth Quarters	1
EPS Growth Years	4
Revenue Growth	81.26x
Revenue Growth Q	69.56x
Revenue Growth Quarters	6x
Revenue Growth Years	3x
Revenue Growth3 Y	333.92x
Revenue Growth5 Y	278.04x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.64
Assets	$1.2B
Cash	$389.6M
Current Assets	$797.3M
Current Liabilities	$137.2M
Debt	$570.7M
Debt EBITDA	$4.97
Debt Equity	$1.29
Debt FCF	$-53.1
Equity	$441.6M
Interest Coverage	5.41
Liabilities	$716.2M
Long Term Assets	$360.5M
Long Term Liabilities	$578.9M
Net Cash	$-181.1M
Net Cash By Market Cap	$-4.06
Net Debt EBITDA	$1.6
Net Debt Equity	$0.41
Tangible Book Value	$441.6M
Tangible Book Value Per Share	$3.12

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	5.81
Inventory Turnover	0.83
Net Working Capital	$293.3M
Quick ratio	4.84
Working Capital	$681.5M
Working Capital Turnover	$0.77

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	2.27%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	-2.27%
200-day SMA	24.03
3Y total return	71.38%
50-day SMA	32.01
50-day SMA vs 200-day SMA	50over200
5Y total return	-12.97%
All Time High	56.31
All Time High Change	-34.91%
All Time High Date	2021-01-13
All Time Low	3.57
All Time Low Change	928.05%
All Time Low Date	2022-06-16
ATR	3.3
Ch YTD	-1.24
High	36.65
High52	37.11
High52 Date	2025-10-01
High52ch	-1.24%
Low	36.65
Low52	28.07
Low52 Date	2025-08-06
Low52ch	30.57%
Ma50ch	14.51%
Price vs 200-day SMA	52.53%
RSI	55.68
RSI Monthly	60.32
RSI Weekly	62.55
Sharpe ratio	1.39x
Sortino ratio	2.62
Total Return	2.27%
Tr YTD	-1.24
Tr1m	20.6%
Tr3m	20.6%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	$113.2M
Operating Income Growth	149.9
Operating Income Growth Q	303.6
Operating margin	21.35

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	135,104,730%
Net Borrowing	361,370,073.2
Shares Insiders	4.63%
Shares Institutions	77.2%
Shares Qo Q	0.44%
Shares Yo Y	-2.27%
Short Ratio	14.07

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-63.5M
Average Volume	3,919.9x
Bv Per Share	3.12
CAPEX	$-181,753
Ch1m	20.6
Ch1y	-2.27
Ch3m	20.6
Ch3y	71.38
Ch5y	-12.97
Ch6m	-1.24
Change	-1.24%
Change From Open	0
Close	37.11
Days Gap	-1.24
Depreciation Amortization	60,881.7
Dollar Volume	5,900.7
Earnings Date	2026-05-06
EBIT	$113.2M
EBITDA	$113.3M
EPS	$2.17
F Score	3
FCF	$-10.7M
FCF EV Yield	-0.23x
Financing CF	232,645,611
Fiscal Year End	December
Founded	1,993
Graham Number	15.32758
Graham Upside	-58.18
Income Tax	$-257.2M
Investing CF	12,774,978
Is Primary Listing	0
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Ma150	26.48
Ma150ch	38.42%
Ma20	31.88
Ma20ch	14.98%
Net CF	234,855,427
Open	36.65
Ppne	4,753,904.2
Price Date	2026-04-21
Price EBITDA	$39.35
Ptbv Ratio	10.09
Relative Volume	0.04x
Revenue	530,377,799x
SBC By Revenue	9.94x
Share Based Comp	52,744,779
Tax By Revenue	-48.49x
Tr6m	-1.24%
Volume	161
Z Score	3.61

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0VGI pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0VGI stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0VGI?

Insider, institutional, and short-interest positioning.

Institutional ownership

+77.2%

Share of float held by funds and institutions

Insider ownership

+4.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LON/0VGI momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

55.7

Neutral momentum band

Price vs 200-day MA

+52.5%

50/200-day relationship not available

Beta (5Y)

n/a

Sensitivity to the broader market

Sharpe ratio

1.39

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0VGI

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0VGI stock rating?

lon/0VGI is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0VGI analysis?

The full report lives at /stocks/lon/0VGI/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0VGI?

The latest report frames lon/0VGI around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0VGI page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.